** Shares of biotech firm Immunic IMUX.O down 12% to 80 cents in extended trading as it looks to raise equity

** New York -based IMUX announces public offering of pre-funded warrants and warrants to purchase shares; deal not disclosed

** Co intends to use net proceeds to fund clinical trials and operations and other general purposes

** Co says its lead drug, vidofludimus calcium (IMU-838), currently in phase III trials for treatment of relapsing multiple sclerosis, for which top-line data is expected to be available end of 2026

** Multiple sclerosis is a chronic autoimmune disease that affects the central nervous system

** Leerink sole bookrunner for proposed offering

** With ~95.8 mln shares outstanding as of May 14, per the SEC prospectus filing, giving IMUX ~$87 mln market cap

** IMUX shares on Weds rose 2 cents to close at 91 cents. Stock hit 52-week high of $2.11 in Sept

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))